Experiment Protocol Biomedical Engineer in United States San Francisco –Free Word Template Download with AI

This Experiment Protocol outlines the procedures for evaluating a novel biosensor technology designed for continuous glucose monitoring (CGM). The research is conducted by a team of Biomedical Engineers at the San Francisco Biomedical Research Institute, located in the heart of the United States, San Francisco. The primary objective is to assess the accuracy, reliability, and safety of the biosensor in a controlled clinical environment.

San Francisco, known for its cutting-edge medical research and innovation, provides an ideal setting for this study. The city's diverse population and advanced healthcare infrastructure contribute to the robustness of the data collected. This protocol adheres to all relevant federal and state regulations, including those set by the Food and Drug Administration (FDA) and the California Department of Public Health.

The main objectives of this experiment are:

• To evaluate the accuracy of the biosensor in measuring blood glucose levels compared to standard laboratory methods.
• To assess the reliability and consistency of the biosensor over a 14-day period.
• To monitor any adverse events or side effects associated with the use of the biosensor.
• To gather user feedback on the ease of use and comfort of the biosensor.

3.1 Study Design

This is a prospective, single-arm, open-label study involving 50 participants with type 1 diabetes. Participants will be recruited from local clinics in San Francisco and will be monitored for 14 days.

3.2 Participant Selection

Inclusion criteria:

• Age 18-65 years
• Diagnosed with type 1 diabetes for at least 1 year
• Stable insulin regimen
• Willingness to provide informed consent

Exclusion criteria:

• Pregnancy or breastfeeding
• History of severe hypoglycemia unawareness
• Known allergies to adhesive materials
• Participation in another clinical trial within the past 30 days

3.3 Procedure

Participants will be trained on the use of the biosensor by a Biomedical Engineer. The biosensor will be applied to the upper arm, and participants will be instructed to record their glucose readings twice daily using both the biosensor and a standard glucometer. Blood samples will be collected at baseline, day 7, and day 14 for laboratory analysis.

3.4 Data Collection

Data will be collected through:

• Electronic diaries maintained by participants
• Regular follow-up visits with the research team
• Adverse event reporting forms

This study has been reviewed and approved by the Institutional Review Board (IRB) of the San Francisco Biomedical Research Institute. All participants will provide written informed consent before enrollment. Confidentiality of participant data will be maintained in accordance with the Health Insurance Portability and Accountability Act (HIPAA).

Data will be analyzed using statistical software. The primary outcome measure is the mean absolute relative difference (MARD) between the biosensor readings and laboratory glucose measurements. Secondary outcomes include the incidence of adverse events and user satisfaction scores.

This Experiment Protocol provides a comprehensive framework for evaluating the novel biosensor technology. By conducting this study in San Francisco, we leverage the city's advanced medical infrastructure and diverse population to ensure the validity and generalizability of our findings. The insights gained will contribute to the advancement of Biomedical Engineering and improve the quality of life for individuals with diabetes.